Topoisomerase II-Alpha gene copy number alterations in ERBB2-Positive primary breast carcinomas: A fluorescence in situ hybridization study

A Colomer1, N Erill1, M Górriz1,2, M Verdú2, R Roman1, R Ibáñez1, C Cordon-Cardo1 and X Puig1,2.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and 2Histopat Laboratoris, Barcelona, Spain.

Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems […]


Molecular protocol for HER2/neu analysis in breast carcinoma

Montse Verdú1, Anna Colomer2, Ruth Román2, Nadina Erill2, Miquel Calvo3, Abelardo Moreno1, Carlos Cordon-Cardó4, Xavier Puig 1,2.

1HISTOPAT Laboratoris, Barcelona. 2BIOPAT, Biopatologia Molecular, Barcelona. 3Departament d’Estadística de la Universitat de Barcelona, Barcelona y 4Division of Molecular Pathology,  Memorial Sloan-Kettering Cancer Center,  New York, USA.

The HER2/neu proto-oncogen is frequently amplified in breast cancer, and serves as a […]


HER-2/neu status in breast carcinoma: overexpression versus amplification

Verdú M1, Colomer A2, Román R2, Erill N2, Moreno A1, Cordón-Cardo C1,2, Puig X1,2.

1HISTOPAT Laboratoris & 2BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) […]


Marcadores de pronóstico en el carcinoma de mama

M. Guix Pericas 1,2, C. Cordón Cardó 1,2,3, M. A. Cañadas Bouzas 1, A. Colomer Valero 2,  X. Puig Torrus 1,2.

1HISTOPAT S.A. Laboratoris. 2BIOPAT. Biopatologia molecular S.L. Grup Assistència. Barcelona. 3Memorial Sloan Kettering Cancer Center. Division of Molecular Pathology. Nueva York.


El carcinoma de mama es una de las neoplasias malignas más frecuentes y una de […]